3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Polycystic Ovary Syndrome
1
Overweight
1
Obesity
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
pembrolizumab
1022
Carboplatin
962
Paclitaxel
933
Gemcitabine
794
Cisplatin
749
Docetaxel
683
Bevacizumab
610
Pemetrexed
502
Nivolumab
487
Cyclophosphamide
469
Capecitabine
461
Fluorouracil
418
Dexamethasone
403
Rituximab
372
Oxaliplatin
348
Injections
343
atezolizumab
297
Trastuzumab
297
Leucovorin
287
Cetuximab
282
Irinotecan
268
130-nm albumin-bound paclitaxel
253
Prednisone
245
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
Fulvestrant
217
fludarabine
216
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
licogliflozin
×
Clear all
NCT03152591
2021-01-05
PCOS
Novartis
Phase 2
Completed
29 enrolled
24 charts